Compare Biogen Inc (BIIB) vs Crowdstrike Holdings Inc (CRWD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Crowdstrike Holdings Inc — how do they compare? Biogen Inc trades at $195.45 (market cap $28.34B), while Crowdstrike Holdings Inc trades at $207.72 (market cap $214.58B). The key difference: Crowdstrike Holdings Inc is far larger — about 7.6× Biogen Inc's market cap, and Crowdstrike Holdings Inc is trading nearer its 52-week high, Biogen Inc nearer its low. Which is the better fit depends on your goals.
| BIIB | CRWD | |
|---|---|---|
Market Cap | $28.34B | $214.58B |
Sector | Health | Technology |
52-Week High | $216.63 | $210.73 |
52-Week Low | $122.68 | $87.56 |
Enterprise Value | $30.62B | $210.85B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
CrowdStrike (CRWD) trades at $187.91, up 0.39% on the day, with a bullish technical signal and strong support near $185. The stock has delivered three consecutive quarterly EPS beats, with Q2 2026 expected at $0.29. Revenue growth remains robust, rising from $1.5B in 2022 to $4.0B in 2025, though net margins are slightly negative. A recent 4-for-1 stock split on July 2, 2026, has increased accessibility amid heightened investor interest in AI-driven cybersecurity.
Outlook is supported by solid cash flow growth and dominant market positioning, but premium valuations (P/E 765, P/S 37) pose risks if growth decelerates. Analyst consensus is strongly bullish with a $184.39 price target, though competitive pressures and execution challenges remain key watchpoints for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Crowdstrike Holdings Inc
CrowdStrike Holdings provides cybersecurity products and services aimed at protecting organizations from cyberthreats. It offers cloud-delivered protection across endpoints, cloud workloads, identity and data, and threat intelligence, managed security services, IT operations management, threat hunting, identity protection, and log management. CrowdStrike went public in 2019 and serves customers worldwide.
Read more on CRWD →
